학술논문

Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases
Document Type
article
Source
European Journal of Nuclear Medicine and Molecular Imaging. 48(7)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Acquired Cognitive Impairment
Neurosciences
Behavioral and Social Science
Biomedical Imaging
Clinical Research
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Bioengineering
Alzheimer's Disease
Dementia
Neurodegenerative
Brain Disorders
Aging
Detection
screening and diagnosis
4.1 Discovery and preclinical testing of markers and technologies
Neurological
Aged
Aged
80 and over
Alzheimer Disease
Amyloid beta-Peptides
Brain
Carbolines
Humans
Middle Aged
Neurodegenerative Diseases
Positron-Emission Tomography
tau Proteins
Alzheimer’s disease
Human aging
Neurofibrillary tangles
Tau PET
Other Physical Sciences
Nuclear Medicine & Medical Imaging
Clinical sciences
Language
Abstract
PurposeIn vivo measurement of the spatial distribution of neurofibrillary tangle pathology is critical for early diagnosis and disease monitoring of Alzheimer's disease (AD).MethodsForty-nine participants were scanned with 18F-PI-2620 PET to examine the distribution of this novel PET ligand throughout the course of AD: 36 older healthy controls (HC) (age range 61 to 86), 11 beta-amyloid+ (Aβ+) participants with cognitive impairment (CI; clinical diagnosis of either mild cognitive impairment or AD dementia, age range 57 to 86), and 2 participants with semantic variant primary progressive aphasia (svPPA, age 66 and 78). Group differences in brain regions relevant in AD (medial temporal lobe, posterior cingulate cortex, and lateral parietal cortex) were examined using standardized uptake value ratios (SUVRs) normalized to the inferior gray matter of the cerebellum.ResultsSUVRs in target regions were relatively stable 60 to 90 min post-injection, with the exception of very high binders who continued to show increases over time. Robust elevations in 18F-PI-2620 were observed between HC and Aβ+ CI across all AD regions. Within the HC group, older age was associated with subtle elevations in target regions. Mildly elevated focal uptake was observed in the anterior temporal pole in one svPPA patient.ConclusionPreliminary results suggest strong differences in the medial temporal lobe and cortical regions known to be impacted in AD using 18F-PI-2620 in patients along the AD trajectory. This work confirms that 18F-PI-2620 holds promise as a tool to visualize tau aggregations in AD.